{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:22:22Z","timestamp":1761920542258,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.msard.2019.02.019","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T03:14:30Z","timestamp":1550114070000},"page":"187-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings"],"prefix":"10.1016","volume":"30","author":[{"given":"Jan","family":"Kolcava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Hulova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Benesova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Bednarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Stourac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2019.02.019_bib0001","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jns.2016.03.050","article-title":". Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain","volume":"365","author":"Aladro","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2019.02.019_bib0002","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":". Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2019.02.019_bib0003","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.02.019_bib0028","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann. Neurol.."},{"key":"10.1016\/j.msard.2019.02.019_bib0004","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jcv.2008.06.009","article-title":". BK virus antibody titers and intensity of infections after renal transplantation","volume":"43","author":"Bohl","year":"2008","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.msard.2019.02.019_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40893-017-0027-1","article-title":"May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter 2 years-prospective study","volume":"2","author":"Amico","year":"2017","journal-title":"Mult. Scler. Demyelinating Disord."},{"key":"10.1016\/j.msard.2019.02.019_bib0006","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virusinduced demyelinating disease of the human brain","volume":"25","author":"Ferenczy","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.msard.2019.02.019_bib0007","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","article-title":"MRI criteria for the diagnosis of multiple sclerosis: MEGNIMS concensus guidelines","volume":"15","author":"Filippi","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2019.02.019_bib0008","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.02.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174005","article-title":"Stability and predictive value of anti-JCV antibody index in multiple sclerosis: a 6-year longitudinal study","volume":"12","author":"Hegen","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2019.02.019_bib0011","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"11","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2019.02.019_bib0012","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1212\/NXI.0000000000000029","article-title":"IV immunoglobulin confounds JC virus antibody serostatus determination","volume":"1","author":"Kister","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2019.02.019_bib0013","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/ane.12475","article-title":"Anti-JC virus seroprevalence in a Finnish MS cohort","volume":"133","author":"Kolasa","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2019.02.019_bib0014","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":". A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.msard.2019.02.019_bib0015","first-page":"117","article-title":"Stratification and monitoring of natalizumab associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2019.02.019_bib0016","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":". Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2019.02.019_bib0017","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1212\/WNL.0000000000003081","article-title":"Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay","volume":"87","author":"Ontaneda","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.02.019_bib0018","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"Outteryck","year":"2013","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2019.02.019_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002650","article-title":"Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients","volume":"8","author":"Pastrana","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.msard.2019.02.019_bib0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00430-011-0200-7","article-title":"Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer","volume":"201","author":"Pastrana","year":"2012","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.msard.2019.02.019_bib0021","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.02.019_bib0022","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2019.02.019_bib0023","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2019.02.019_bib0024","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.02.019_bib0025","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2019.02.019_bib0026","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":". Anti-JC virus antibodies in a large German natalizumabtreated multiple sclerosis cohort","volume":"78","author":"Trampe","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.02.019_bib0027","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/ene.12988","article-title":". High cumulative JC virus seroconversion rate during long-term use of natalizumab","volume":"23","author":"Vennegoor","year":"2016","journal-title":"Eur. J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819300938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819300938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:46:58Z","timestamp":1761900418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819300938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":27,"alternative-id":["S2211034819300938"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.02.019","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}